目的 分析遼寧省腫瘤醫(yī)院2020-2022年小分子酪氨酸激酶抑制劑的使用情況以及變化趨勢，為臨床安全合理經(jīng)濟(jì)用藥提供參考依據(jù)。方法 收集2020-2022年遼寧省腫瘤醫(yī)院小分子酪氨酸激酶抑制劑使用數(shù)據(jù)，分析銷售金額、用藥頻度（DDDs）、限定日費(fèi)用（DDC）以及排序比（B/A）。結(jié)果 2020-2022年小分子酪氨酸激酶抑制劑銷售金額逐年增長。奧希替尼連續(xù)3年銷售金額穩(wěn)居第1位。侖伐替尼銷售金額大幅增長，而吉非替尼銷售金額大幅下降。奧希替尼、?？颂婺?、吉非替尼的DDDs近3年穩(wěn)居前3位。侖伐替尼DDDs大幅上升，而索拉非尼DDDs大幅下降。普拉替尼、賽沃替尼和洛拉替尼的DDC值偏高。?？颂婺?、吉非替尼、厄洛替尼、索拉非尼和達(dá)可替尼DDC值較低。從B/A可以看出，2022年?？颂婺岷图翘婺岬腂/A>1，賽沃替尼、培唑帕尼和阿來替尼的排序比<1。結(jié)論 2020-2022年遼寧省腫瘤醫(yī)院小分子酪氨酸激酶抑制劑的使用總體上較為合理，但仍需進(jìn)一步加強(qiáng)監(jiān)管力度，保障患者用藥的安全、有效和經(jīng)濟(jì)。

Objective To analyze the usage and variation tendency of small-molecule tyrosine kinase inhibitors in Liaoning Cancer Hospital & Institute from 2020 to 2022, and provide references for standardizing the management and rational application. Methods Consumption sum, DDDs, DDC, and drug B/A of small-molecule tyrosine kinase inhibitors in Liaoning Cancer Hospital& Institute from 2020 to 2022 were analyzed statistically. Results From 2020 to 2022, the sales amount of small-molecule tyrosine kinase inhibitors increased year by year. Osimertinib ranked first in sales in three years. Lenvatinib sales increased significantly, while gefitinib sales decreased significantly. Osimertinib, icotinib, and gefitinib have been in the top three for DDDs in the past three years. Lenvatinib DDDs rose sharply, while sorafenib DDDs decreased sharply. Pralsetinib, savolitinib, and lorlatinib have high DDC values. Icotinib, gefitinib, erlotinib, sorafenib, and dacomitinib DDC values are low. It can be seen from the ranking ratio that the B/A of icotinib and gefitinib in 2022 is >1, and the B/A of savolitinib, pazopanib, and alectinib is <1. Conclusion From 2020 to 2022, the use of small-molecule tyrosine kinase inhibitors in Liaoning Cancer Hospital & Institute is generally reasonable. However, it is still necessary to further strengthen supervision to ensure the safety, effectiveness and economy of treatment drugs.

R979.1

遼寧省腫瘤醫(yī)院質(zhì)譜課題項(xiàng)目（ZP202019）